Skip to main content
NIH funding notice RFA-DA-23-008

Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required)

Closed on November 12, 2024.

Posted
May 16, 2022
Close date
November 12, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,235,537 in first-year total cost, median $617,769.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 SUY-E (M2)]2

Most frequent institutions

  1. UT SOUTHWESTERN MEDICAL CENTER1
  2. WAKE FOREST UNIVERSITY HEALTH SCIENCES1
Competing awards under RFA-DA-23-008 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025RESTORE (Recovery and Engagement for STimulant users On Re-entry)1R61DA064030-01NIJHAWAN, ANK ELISABETHSPRINGER, SANDRA ANNUT SOUTHWESTERN MEDICAL CENTER, TX$660,104ZDA1
2025Hybrid Trial of Peer-Supported Affect Regulation and Contingency Management to Improve HIV Prevention Outcomes in the Southern United States1R61DA064042-01LANCASTER, KATHRYN ELIZABETHWAKE FOREST UNIVERSITY HEALTH SCIENCES, NC$575,433ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.